Document is current
Any future updates will be listed below
-
Authors
Steffens, Sabine https://orcid.org/0000-0002-6892-9751
Schröder, Katrin https://orcid.org/0000-0002-3099-526X
Krüger, Martina https://orcid.org/0000-0003-2446-5526
Maack, Christoph https://orcid.org/0000-0003-3694-4559
Streckfuss-Bömeke, Katrin https://orcid.org/0000-0001-5137-7228
Backs, Johannes https://orcid.org/0000-0002-2322-2699
Backofen, Rolf https://orcid.org/0000-0001-8231-3323
Baeßler, Bettina https://orcid.org/0000-0002-3244-3864
Devaux, Yvan https://orcid.org/0000-0002-5321-8543
Gilsbach, Ralf https://orcid.org/0000-0002-0895-1535
Heijman, Jordi https://orcid.org/0000-0002-1418-108X
Knaus, Jochen https://orcid.org/0000-0002-7470-3791
Kramann, Rafael https://orcid.org/0000-0003-4048-6351
Linz, Dominik https://orcid.org/0000-0003-4893-0824
Lister, Allyson L.
Maatz, Henrike https://orcid.org/0000-0002-9232-6272
Maegdefessel, Lars https://orcid.org/0000-0001-5228-2634
Mayr, Manuel https://orcid.org/0000-0002-0597-829X
Meder, Benjamin https://orcid.org/0000-0003-0741-2633
Nussbeck, Sara Y. https://orcid.org/0000-0003-1223-6494
Rog-Zielinska, Eva A.
Schulz, Marcel H. https://orcid.org/0000-0002-1252-3656
Sickmann, Albert https://orcid.org/0000-0002-2388-5265
Yigit, Gökhan https://orcid.org/0000-0003-2777-0198
Kohl, Peter https://orcid.org/0000-0003-0416-6270
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SFB1123 (DFG #238187445), SFB1425 (DFG #422681845), SFB1525 (DFG #453989101), GRK 2824 (DFG #465640801))
Universitätsklinikum Freiburg
- License Information
-
More Information
Article History
Received: 7 April 2023
Accepted: 1 September 2023
First Online: 17 October 2023
Declarations
:
: Christoph Maack is an advisor to Amgen, Boehringer Ingelheim, Bristol Myers Squibb, NovoNordisk and Servier; received speaker honoraria from AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Berlin Chemie, Novartis, and NovoNordisk. Johannes Backs is a founder of Revier Therapeutics, co-founder of Artemes Bio, collaborates with the Lead Discovery Center Dortmund and NovoNordisk on a drug development program, and received a Golden Ticket from NovoNordisk for lab space in Biolabs Heidelberg. Bettina Baeßler has no competing interest directly related to this work, and is co-founder and CEO of Lernrad GmbH, and received modest lecture honorary from Bayer Vital GmbH. Rafael Kramann has no competing interest directly related to this work, and is co-founder and shareholder of Sequantrix GmBH, has grants from Travere Therapeutics, Galapagos, Chugai and Novo Nordisk and is a consultant for Bayer, Pfizer, Novo Nordisk and Gruenenthal. Maastricht University and The University of Copenhagen received modest lecture and consulting honorary and research support from Bayer, Biosense Webster, Astra Zeneca, Biotronik, Medtronic, Microport, NovoNordisk on behalf of Dominik Linz. Lars Maegdefessel is a scientific consultant for NovoNordisk, DrugFarm, and Angiolutions, and has received research funding from Roche Diagnostics and NovoNordisk. Benjamin Meder was a member of the Scientific Advisory Board for Fleischhacker (Malaysia) until 2020. Sabine Steffens, Katrin Schröder, Martina Krüger, Katrin Streckfuss-Bömeke, Ralf Backofen, Yvan Devaux, Ralf Gilsbach, Jordi Heijman, Jochen Knaus, Allyson L. Lister, Henrike Maatz, Manuel Mayr, Sara Y. Nussbeck, Marcel H. Schulz, Albert Sickmann, Eva A. Rog-Zielinska, Gökhan Yigit, and Peter Kohl have no conflicts to disclose.
